Alimera Sciences Stock Price and Value Analysis

Should you buy Alimera Sciences stock? (NasdaqGM:ALIM). Let's see how it does in our automated value investing analysis system.

ALIM Free Cash Flow Trend

Free Cash Flow trendline for ALIM
Free Cash Flow trendline for Alimera Sciences

Hmm, we can't give any reliable projection for Alimera Sciences's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company has fluctuating growth.
  • This company is solid.
  • This stock looks overpriced.
  • This company is not making money.
  • This company pays no dividend.

Inside the ALIM Numbers

ALIM Price
(Alimera Sciences stock price per share)
PE Ratio versus Sector 91% lower than other Healthcare stocks
PE Ratio versus Industry 90% lower than other Drug Manufacturers - Major stocks
Cash Yield -128.14%
Free Cash Flow Jitter 28%

Is Alimera Sciences Stock on Sale?

Based on our analysis, we believe that you should not buy Alimera Sciences right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy ALIM Stock?

Does Alimera Sciences have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.